Body Contouring
Mounjaro (Weight Loss Injection)
The clinically approved breakthrough in medical weight loss
At YourHealthFirst Clinic, we provide medically supervised weight-management support for eligible patients seeking a structured and evidence-based approach to weight loss. Our Wimpole Street Weight Management Service in London is delivered by trained and experienced healthcare professionals, with an emphasis on appropriate patient assessment, treatment suitability, ongoing monitoring and safe use of prescription weight-management medicines.
Our clinicians assess your medical history, current medicines, health conditions, BMI and weight-management goals before deciding whether prescription treatment is appropriate.
Mounjaro® (Tirzepatide) Weight Management
Mounjaro contains tirzepatide, a prescription medicine that acts on two hormone receptors: GIP and GLP-1. For weight management, Mounjaro is used alongside a reduced-calorie diet and increased physical activity in eligible adults with obesity, or adults who are overweight and have weight-related health problems. Tirzepatide works partly by regulating appetite and increasing feelings of fullness, which can help reduce food intake and support weight loss.
What Does the Clinical Evidence Show?
Mounjaro has been studied extensively in large clinical trials. In the 72-week SURMOUNT-1 study involving 2,539 adults, average weight loss was approximately 16.0% with 5mg, 21.4% with 10mg and 22.5% with 15mg — compared with approximately 2.4% in the placebo group.
Individual results vary, and clinical-trial results should not be interpreted as a guarantee of the amount of weight an individual patient will lose.
Mounjaro Dosage
Treatment normally starts at 2.5mg once weekly. The UK product information states that the starting dose is 2.5mg once a week for four weeks, followed by an increase to 5mg once weekly.
If clinically appropriate, your prescriber may increase the dose in 2.5mg increments, with patients remaining on each dose for at least four weeks before increasing. Available adult doses include 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Your dose should only be changed following advice from your prescribing clinician.
Key Facts
Results
Significant weight reduction over 12–72 weeks
Starting From
From £250 per pen
Location
2 Wimpole Street, London W1G 0EB
Book a Consultation
Begin with a personal consultation with Sofia to discuss your goals and confirm suitability.
Key Benefits
- Medical-led weight management — treatment begins with an individual clinical assessment
- Based at 2 Wimpole Street, London W1G 0EB — in the heart of London's medical district
- Individualised treatment and dosing based on your clinical circumstances and response
- Safety-focused care — screened for relevant conditions, medicines and contraindications
- Ongoing clinical support and guidance throughout your treatment journey
What Areas Can Be Treated?
Mounjaro (Weight Loss Injection) can be used on various areas of the face and body to rejuvenate the skin, improve texture and stimulate natural healing.
Who Is It For?
Mounjaro (Weight Loss Injection) is ideal for:
Who May Not Be Suitable for Mounjaro
This treatment may not be suitable for everyone. It is not recommended for individuals with the following conditions, to ensure your safety and the best possible results.
Not sure if you're suitable?
Book a consultation with our specialist to discuss your medical history and find out if this treatment is right for you.
Book a ConsultationImportant
Mounjaro — Administration, Storage & Safety
Mounjaro is administered as a subcutaneous injection. Please follow the official Mounjaro Instructions for Use and the advice provided by your prescriber.
Where Is Mounjaro Injected?
- Abdomen
- Thigh
- Back of the upper arm
- Injection sites should be rotated. If another injectable medicine such as insulin is being used, your healthcare professional will advise you on appropriate injection sites.
How Should Mounjaro Be Stored?
- Unused Mounjaro KwikPens should be stored in a refrigerator at 2°C–8°C and must not be frozen.
- After first use, the KwikPen can be stored unrefrigerated at a temperature not exceeding 30°C for up to 30 days, after which it must be discarded.
Important Safety Information
- Most commonly reported side effects are gastrointestinal and can be more noticeable when treatment is started or the dose is increased.
- Possible side effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite.
- Other adverse effects can occur, including gallstones, gallbladder inflammation, injection-site reactions and, less commonly, pancreatitis.
- Severe, persistent abdominal pain — particularly if it radiates to the back and is accompanied by nausea or vomiting — requires urgent medical assessment because it may indicate acute pancreatitis.
Your Weight Management Journey
Our approach is based on medical assessment rather than simply supplying a weight-loss injection.
1. Initial Assessment
We review your health history, BMI, current medication, relevant medical conditions and weight-management goals.
2. Suitability Assessment
A qualified prescriber determines whether Mounjaro is clinically appropriate for you.
3. Treatment Plan
If prescribed, you receive guidance on the appropriate starting dose, administration, lifestyle measures and monitoring.
4. Ongoing Monitoring
Your progress, treatment response, side effects and dose requirements can be reviewed throughout your journey.
5. Long-Term Weight Management
Weight management involves more than medication. Nutrition, physical activity, behavioural factors and sustainable lifestyle changes remain important parts of treatment.
How Does Mounjaro Work?
Tirzepatide targets appetite and digestion through four complementary mechanisms.
Appetite Regulation
Mounjaro can reduce hunger and food cravings, helping you manage portion sizes and overall food intake.
Increased Satiety
The medicine can help you feel fuller for longer after eating.
Slower Gastric Emptying
Tirzepatide can delay the movement of food from the stomach, contributing to feelings of fullness.
Metabolic Effects
Tirzepatide also affects blood-glucose regulation through its GIP and GLP-1 activity.
Frequently Asked Questions
Everything you need to know about mounjaro (weight loss injection) at YourHealthFirst Clinic.
After an initial consultation and health assessment to confirm suitability, you self-administer a once-weekly injection via a pre-filled pen. The dose is gradually increased over time under medical supervision.
In the 72-week SURMOUNT-1 study involving 2,539 adults, average weight loss was approximately 16.0% with 5mg, 21.4% with 10mg and 22.5% with 15mg — compared with approximately 2.4% in the placebo group. Individual results vary, and clinical-trial results should not be interpreted as a guarantee of the amount of weight an individual patient will lose.
Mounjaro is a clinically approved and extensively studied medication. It is only prescribed following a full health assessment, with ongoing monitoring throughout your programme to ensure it remains appropriate and safe for you.
Most commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite — and can be more noticeable when treatment is started or the dose is increased. Other adverse effects can occur, including gallstones, gallbladder inflammation and injection-site reactions. Severe, persistent abdominal pain, particularly if it radiates to the back and is accompanied by nausea or vomiting, requires urgent medical assessment as it may indicate acute pancreatitis.
Mounjaro is administered via a simple pre-filled pen with a very fine needle, and most patients find self-injection straightforward and minimally uncomfortable.
The starting dose is 2.5mg once a week for four weeks, followed by an increase to 5mg once weekly. If clinically appropriate, your prescriber may increase the dose in 2.5mg increments, with patients remaining on each dose for at least four weeks before increasing. Available adult doses include 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Your dose should only be changed following advice from your prescribing clinician.
Weight reduction is progressive over the course of the programme, with meaningful results typically building from around 12 weeks and continuing through to 72 weeks.
Adults with a BMI of 30+ (or 27+ with a weight-related health condition) who have not achieved sufficient results through diet and exercise alone, and who are confirmed medically suitable following a full assessment of medical history, current medicines, health conditions and weight-management goals.
Investigational — Not Yet Available
Retatrutide – What You Need to Know
An investigational next-generation treatment
Retatrutide is not the same medicine as Mounjaro. Retatrutide is an investigational once-weekly triple hormone receptor agonist that targets GLP-1, GIP and Glucagon. It is currently being investigated in Phase 3 clinical trials for obesity and related conditions.
Recent Phase 3 results have reported substantial weight loss in clinical-trial populations. For example, in TRIUMPH-1, participants receiving 12mg retatrutide had an average weight reduction of 28.3% at 80 weeks in the reported study population. These are investigational clinical-trial results and are not a guarantee of individual results.
Important: Retatrutide has not been approved for public use by a regulatory authority and is not currently available as a licensed prescription weight-management medicine. It is not marketed or offered as an available treatment at YourHealthFirst Clinic outside an authorised clinical trial.
Retatrutide — Frequently Asked Questions
Retatrutide has been nicknamed ‘Triple G’ because it targets three different receptors and hormones – GLP-1, glucagon and GIP. Glucagon and GIP are naturally released when you eat food, and play a role in reducing appetite, lowering blood sugar and helping the body burn fat.
Three ways it may support weight loss
- Suppressing appetite and slowing digestion, meaning you're not as hungry as often and feel fuller for longer
- Increasing fat metabolism, so the body breaks down fat quicker
- Increasing insulin sensitivity, which reduces blood sugar and encourages the breakdown of stored fat
Mounjaro acts on two hormone receptors, GIP and GLP-1. Retatrutide is being investigated as a triple agonist, additionally targeting glucagon receptors. In the TRIUMPH-1 Phase 3 trial, participants receiving 12mg retatrutide had an average weight reduction of 28.3% at 80 weeks, compared with an average of 22.5% with the highest dose of Mounjaro over 72 weeks in the SURMOUNT-1 trial. These trials differ in design and duration, so a direct comparison should be treated with caution, and results are not a guarantee of individual outcomes.
In clinical trials, Retatrutide is given using a pen injector, delivered as a subcutaneous injection into the arm, thigh or stomach, once weekly, starting with a lower dose to minimise side effects.
In clinical trials, Retatrutide has been associated with side effects similar to other GLP-1/GIP medicines. Always consult your doctor, nurse or pharmacist before using any new medication.
Commonly reported side effects
- Nausea
- Vomiting
- Constipation
- Diarrhoea
No. Retatrutide has not been approved for public use by a regulatory authority and is not currently available as a licensed prescription weight-management medicine. We are unable to prescribe or sell Retatrutide outside an authorised clinical trial. If you are interested in a currently available, clinically approved option, please ask us about Mounjaro.
Our Prices
Check Our Price ListGet an Appointment
By phone: 0207 225 3582 / 078 1847 4041
By email: info@yourhealthfirst.uk
Opening Hours
Monday to Friday – 10am to 6pm
Saturday – 12pm to 2pm (doctor appointments only)
Sunday & out of hours – by appointment only
Related Treatments
Cryolipolysis (Fat Freezing)
Cryolipolysis is the procedure for you if you want to avoid surgery, eliminate stubborn fat, lose weight and return to your life within a few hours. It effectively targets problem areas including your belly, inner and outer thighs, back and more — a popular alternative to liposuction that zeroes in on fat cells with controlled cooling, freezes them and initiates their elimination.
Learn more →Emsculpt Neo
Emsculpt Neo is the world's first and only non-invasive treatment that simultaneously burns fat and builds muscle using a combination of radiofrequency heating and high-intensity focused electromagnetic energy (HIFEM+). One 30-minute session is equivalent to 20,000 muscle contractions.
Learn more →Aqualyx (Fat Dissolving)
Aqualyx is a clinically proven fat-dissolving injection that permanently destroys fat cells in small, targeted areas. It is an ideal solution for localised fat deposits that are resistant to diet and exercise, such as a double chin, jowls, small abdominal pockets and inner thighs.
Learn more →
